ReviewHeliyon2024
Advancing a food loss and waste bioproduct industry: A critical review of policy approaches for application in an Australian context.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Food loss and waste (FLW) contains an abundance of nutrient components that can be extracted and converted into valuable bioproducts through biorefining (e.g., pharmaceuticals, cosmetics, nutrients). Australia has identified bioproducts from a FLW feedstock as one avenue through which it can meet its commitment to UN Sustainable Development Goal Target 12.3, aiming to halve food waste by 2030. An industry for bioproducts in Australia is, however, nascent and will require targeted and sustained policy intervention to advance in line with the production targets it has set to meet Target 12.3. The aim of this critical review is threefold. Firstly, it draws on the research literature to identify barriers to advancing a bioproduct industry from FLW. Secondly, it constructs a taxonomy of policies available to overcome these barriers and support industry development. Finally, it applies the taxonomy to established policy settings in Australia (examining both national settings and Queensland state settings) and the European Union (EU), where the industry and associated policy is more mature. Australia has few national policies directly targeting a bioproduct industry. A comparative assessment of policy settings allows this review to identify lessons Australia can draw from the EU experience as it advances its own industry. Findings demonstrate a complex and fragmented policy landscape. Key recommendations from the literature emphasise the need to establish coordinated strategic instruments; target research and development opportunities for optimised, sustainable processes; and implement appropriate incentives to establish a 'level playing field', as technology readiness increases. The critical requirement for policy stability and coherence, flags the need to lay groundwork policy in this area as a priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.